Study guide
11.3 Acute Diabetic & Metabolic Crises: DKA, HHS & Severe Hypoglycemia
Nursing Council of Jamaica Licensure Examination / Regional Examination for Nurse Registration NCJ RENR
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, NCJ Registration & the RENR Blueprint
1.1 NCJ, the Regional Councils, CXC & the Seven-Domain RENR Blueprint 1.2 Paper Format, Cognitive Levels, Exam-Day Rules & Pacing 1.3 Eligibility, Registration, Results, Reviews, Resits & NCJ Licensure
2 Chapter 2: Professional Conduct, Ethics & Legal Framework
2.1 Ethical Principles, Code of Ethics & Patient Rights 2.2 Informed Consent, Confidentiality & Jamaican Health Law 2.3 Professional Boundaries, Accountability & Incident/Error Reporting
3 Chapter 3: Health Promotion, Community Health & Wellness Maintenance
3.1 Primary Health Care, Immunization Schedules & Cold Chain Integrity 3.2 Nutrition Across the Lifespan & Maternal-Infant Wellness 3.3 Epidemiology, Vector-Borne Disease Control & Chronic Disease Prevention 3.4 Health Education, Teaching-Learning & the Determinants of Health 3.5 Communicable Disease Nursing: HIV, STIs, Tuberculosis & Leptospirosis
4 Chapter 4: Nursing Leadership, Management & Health Systems
4.1 Principles of Ward Management, Prioritization & Patient Assignment 4.2 Effective Delegation, Scope of Practice & Supervision of Unlicensed Personnel 4.3 Clinical Quality Improvement, Safety Audits & Risk Management 4.4 Disaster Preparedness, Infection Surveillance & Institutional Emergency Protocols 4.5 Leadership Styles, Management Functions, Change & Conflict Management 4.6 Caribbean Health Systems, Regional Agencies & Contemporary Health Issues
5 Chapter 5: Therapeutic Communication, Collaboration & Documentation
5.1 Principles of Therapeutic Communication & Patient-Centered Interviewing 5.2 Structured Clinical Handoffs, SBAR Technique & Critical Result Reporting 5.3 Overcoming Communication Barriers, Cultural Competence & Conflict De-escalation 5.4 Documentation, Health Records & Health Information Technology
6 Chapter 6: Nursing Practice: Nursing Process, Asepsis & Pharmacology
6.1 The Nursing Process, Nursing Diagnosis & Holistic Health Assessment 6.2 Principles of Medical and Surgical Asepsis, Standard Precautions & Isolation 6.3 Pharmacological Principles, High-Alert Medications & Safe Administration 6.4 Dosage Calculations, IV Flow Rates & Pediatric/Geriatric Dose Adjustments 6.5 Intravenous Therapy, Fluid/Electrolyte Balance & Blood Transfusion Safety
7 Chapter 7: Nursing Practice: Adult Medical-Surgical, Haematology & Oncology Care
7.1 Preoperative, Intraoperative & Postoperative Nursing Care 7.2 Cardiovascular & Respiratory System Disorders and Clinical Interventions 7.3 Gastrointestinal, Endocrine & Renal Disorders Management 7.4 Musculoskeletal, Neurological & Integumentary Care and Wound Healing 7.5 Haematology & Sickle Cell Disease 7.6 Oncology, Palliative & End-of-Life Care
8 Chapter 8: Nursing Practice: Maternal, Newborn & Reproductive Health
8.1 Antenatal Assessment, Normal Labor, Delivery & Postpartum Care 8.2 Neonatal Assessment, APGAR Scoring & Newborn Nursing Care 8.3 Reproductive Health, Family Planning & Gynaecological Conditions
9 Chapter 9: Nursing Practice: Child, Mental Health & Older Adult Care
9.1 Pediatric Growth, Developmental Milestones & Common Childhood Illnesses 9.2 Psychiatric-Mental Health Nursing, Psychopharmacology & Crisis Intervention 9.3 Depression, Substance Use Disorders & Alcohol Withdrawal 9.4 Care of the Older Adult: Delirium, Dementia, Falls & Healthy Ageing
10 Chapter 10: Clinical Decision Making: Acute Assessment & Critical Interventions
10.1 Systematic Primary and Secondary Patient Assessment (ABCDE Approach) 10.2 Early Warning Scores, Recognizing Clinical Deterioration & Escalation 10.3 Shock Syndromes: Hypovolemic, Cardiogenic, Septic & Anaphylactic 10.4 Acute Respiratory Failure, Airway Emergencies & Oxygen Delivery Modalities
11 Chapter 11: Clinical Decision Making: Complex Emergencies, Resuscitation & Trauma
11.1 Cardiopulmonary Resuscitation, Life Support Protocols & Arrhythmia Recognition 11.2 Acute Coronary Syndromes & Cerebrovascular Accidents (Stroke) 11.3 Acute Diabetic & Metabolic Crises: DKA, HHS & Severe Hypoglycemia 11.4 Trauma, Burns, Poisoning & Environmental Emergencies
12 Chapter 12: Professional Development & Evidence-Based Practice
12.1 Reflective Nursing Practice & Clinical Competence Assessment 12.2 Evidence-Based Practice, Research Utilization & Nursing Quality 12.3 Continuing Professional Education, NCJ License Renewal & Lifelong Learning
11.3 Acute Diabetic & Metabolic Crises: DKA, HHS & Severe Hypoglycemia
Key Takeaways Explain This Topic AI
Under the 2024 ADA/EASD/JBDS consensus, DKA needs glucose of 11.1 mmol/L (200 mg/dL) or more (or known diabetes), beta-hydroxybutyrate of 3.0 mmol/L or more, and pH below 7.3 and/or bicarbonate below 18 mmol/L.
HHS (2024 consensus) is glucose of 33.3 mmol/L (600 mg/dL) or more, calculated effective osmolality above 300 mOsm/kg, no significant ketonaemia, pH of 7.3 or more and bicarbonate of 15 mmol/L or more.
Fluids come first: about 1 L/h of 0.9% saline in severe hypovolaemia, then 5–10% dextrose is added once glucose falls below 13.9 mmol/L (250 mg/dL) while the insulin infusion continues.
Insulin is delayed if serum potassium is below 3.5 mmol/L (2024 consensus) until potassium is replaced, because insulin drives potassium into cells and can cause fatal arrhythmias.
Severe hypoglycemia ( < 54 mg/dL < 54\text{ mg/dL} < 54 mg/dL or symptomatic neuroglycopenia) requires immediate intervention: oral Rule of 15 (15–20 g simple carbohydrates) if alert and able to swallow, or 25–50 mL of 50 % 50\% 50% Dextrose (D50W) IV push or 1 mg IM Glucagon if obtunded or NPO, followed by retesting in 15 minutes.
Last updated: October 2026
Acute Diabetic & Metabolic Crises: DKA, HHS & Severe Hypoglycemia
Clinical Core: Acute metabolic derangements in diabetes mellitus represent high-acuity medical emergencies requiring meticulous fluid, electrolyte, and hormone management. While Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) share common ground in hyperglycemia and osmotic diuresis, their underlying hormonal landscapes, fluid deficits, and biochemical disturbances differ markedly. Concurrently, severe hypoglycemia poses an immediate threat of irreversible neuroglycopenic neuronal death. The registered nurse must master emergency fluid resuscitation algorithms, enforce rigorous potassium safety gates before insulin delivery, and prevent cerebral edema during glycemic stabilization.
- Pathophysiology & Differential Diagnosis: DKA vs. HHS
- Hormonal Mechanisms and Ketogenesis
Diabetic Ketoacidosis (DKA): Driven by an absolute insulin deficiency combined with marked counter-regulatory hormone excess (glucagon, catecholamines, cortisol, growth hormone). This occurs predominantly in Type 1 Diabetes Mellitus, often precipitated by infection, omitted insulin, acute trauma, or myocardial infarction. In the absolute absence of insulin, tissues cannot take up glucose, prompting massive peripheral lipolysis via hormone-sensitive lipase. Uncontrolled lipolysis floods the liver with free fatty acids, which undergo hepatic β \beta β -oxidation into acidic ketone bodies ( acetoacetate and β \beta β -hydroxybutyrate ). The accumulation of ketoacids overwhelms blood buffer systems, producing a high anion gap metabolic acidosis, compensatory hyperventilation ( Kussmaul respirations to blow off volatile carbonic acid), sweet fruity/acetone breath odor, abdominal pain, nausea, and vomiting.
Hyperosmolar Hyperglycemic State (HHS): Driven by a relative insulin deficiency combined with inadequate fluid intake. This occurs predominantly in older adults with Type 2 Diabetes Mellitus, often triggered by severe infections (pneumonia, urinary sepsis), stroke, glucocorticoid therapy, or acute coronary syndrome. In HHS, the concentration of endogenous insulin is sufficient to suppress adipose lipolysis and prevent hepatic ketogenesis, but insufficient to facilitate peripheral glucose clearance or inhibit hepatic gluconeogenesis. Blood glucose rises unchecked to extreme levels ( > 600 to 1 , 200 mg/dL >600\text{ to }1,200\text{ mg/dL} > 600 to 1 , 200 mg/dL ), causing profound plasma hyperosmolality ( > 320 mOsm/kg >320\text{ mOsm/kg} > 320 mOsm/kg ), severe glucosuria, massive osmotic diuresis, and staggering fluid losses (8 to 10+ liters). The clinical picture is dominated by severe dehydration, hypovolemia, lethargy, stupor, focal neurological deficits, and coma without prominent ketoacidosis.
Clinical and Laboratory Differentiation Table
Diagnostic Dimension Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycemic State (HHS)
Typical Patient Profile Type 1 Diabetes Mellitus; younger clients; rapid onset ( < 24 hours <24\text{ hours} < 24 hours ). Type 2 Diabetes Mellitus; older adults; insidious onset over days to weeks.
Plasma Glucose Level ≥ 200 mg/dL \ge 200\text{ mg/dL} ≥ 200 mg/dL (11.1 mmol/L) or known diabetes (2024 consensus). About 10% of DKA is euglycaemic, for example with SGLT2 inhibitors. ≥ 600 mg/dL \ge 600\text{ mg/dL} ≥ 600 mg/dL (33.3 mmol/L), often far higher.
Arterial / Venous pH < 7.30 <7.30 < 7.30 and/or bicarbonate below 18 (severe DKA: pH < 7.00 <7.00 < 7.00 ). ≥ 7.30 \ge 7.30 ≥ 7.30 .
Serum Bicarbonate ( HCO 3 − \text{HCO}_3^- HCO 3 − ) < 18 mmol/L <18\text{ mmol/L} < 18 mmol/L (severe DKA: < 10 mmol/L <10\text{ mmol/L} < 10 mmol/L ). ≥ 15 mmol/L \ge 15\text{ mmol/L} ≥ 15 mmol/L .
Serum / Urine Ketones β \beta β -hydroxybutyrate ≥ 3.0 mmol/L \ge 3.0\text{ mmol/L} ≥ 3.0 mmol/L (or urine ketones 2+ or more). Below 3.0 mmol/L: no significant ketonaemia.
Serum Anion Gap Elevated ( > 10 to 12 mEq/L >10\text{ to }12\text{ mEq/L} > 10 to 12 mEq/L ) ; calculated as [ N a + ] − ( [ C l − ] + [ H C O 3 − ] ) [Na^+] - ([Cl^-] + [HCO_3^-]) [ N a + ] − ([ C l − ] + [ H C O 3 − ]) . Normal ( < 12 mEq/L <12\text{ mEq/L} < 12 mEq/L ) .
Effective Serum Osmolality Variable. Calculated effective osmolality > 300 mOsm/kg >300\text{ mOsm/kg} > 300 mOsm/kg (or total osmolality > 320 >320 > 320 ).
Total Body Fluid Deficit Moderate: 3 to 6 Liters ( ≈ 100 mL/kg \approx 100\text{ mL/kg} ≈ 100 mL/kg ). Severe: 8 to 10+ Liters ( ≈ 150 to 200 mL/kg \approx 150\text{ to }200\text{ mL/kg} ≈ 150 to 200 mL/kg ) .
Hallmark Clinical Signs Kussmaul breathing, acetone breath odor, nausea, vomiting, abdominal pain. Profound dehydration, tachycardia, altered mental status, stupor, coma, seizures.
- Evidence-Based Nursing Management: The Four Core Pillars
- Pillar 1: Aggressive Intravenous Fluid Resuscitation
Fluid replacement takes precedence over insulin administration. Rehydration expands effective circulating plasma volume, restores renal perfusion, enhances urinary excretion of excess glucose, and reduces circulating counter-regulatory hormone levels.
Hour 1 (Immediate Volume Expansion): In severe hypovolaemia, give 0.9% sodium chloride (or another isotonic crystalloid) at about 1 L/h . Then aim to replace about half the estimated deficit over 8–12 hours (2024 consensus), watching closely for fluid overload in older or cardiac clients.
Subsequent Hours (Cellular Hydration): Evaluate the client's corrected serum sodium , because hyperglycemia draws intracellular water into the vascular space, causing pseudohyponatremia: Corrected [ N a + ] = Measured [ N a + ] + 1.6 × ( Glucose − 100 100 ) \text{Corrected } [Na^+] = \text{Measured } [Na^+] + 1.6 \times \left( \frac{\text{Glucose} - 100}{100} \right) Corrected [ N a + ] = Measured [ N a + ] + 1.6 × ( 100 Glucose − 100 )
If corrected sodium is normal or high ( ≥ 135 mEq/L \ge 135\text{ mEq/L} ≥ 135 mEq/L ): Infuse 0.45% Normal Saline at 250 to 500 mL/hr to provide hypotonic fluid for intracellular hydration.
If corrected sodium is low ( < 135 mEq/L <135\text{ mEq/L} < 135 mEq/L ): Continue 0.9% Normal Saline at 250 to 500 mL/hr .
The Critical Glycemic Transition Point (Preventing Cerebral Edema):
When plasma glucose falls below 250 mg/dL 250\text{ mg/dL} 250 mg/dL (13.9 mmol/L) , add 5% or 10% dextrose to the IV fluids and reduce the insulin infusion to about 0.05 units/kg/h . Keep glucose at about 150–200 mg/dL in DKA (200–250 mg/dL in HHS) until the crisis resolves (2024 consensus). Older protocols switched at 200 mg/dL in DKA and 300 mg/dL in HHS.
Pathophysiological Rationale: Brain cells produce intracellular idiogenic osmoles to maintain cell volume in hyperosmolar states. If extracellular plasma osmolality collapses rapidly due to plunging blood glucose while brain cells remain hyperosmolar, a steep osmotic gradient forms that draws water into cerebral astrocytes, provoking life-threatening cerebral edema (manifesting as acute headache, lethargy, bradycardia, confusion, and papilledema). Adding dextrose prevents rapid osmolar collapse and hypoglycemia while permitting uninterrupted IV insulin infusion to clear ketoacids.
Pillar 2: The Potassium Safety Gate (Non-Negotiable Resuscitation Rule)
During acute DKA and HHS, clients suffer massive total-body potassium depletion from osmotic diuresis and urinary potassium wasting. However, baseline serum potassium may appear falsely normal or elevated due to extracellular shifts driven by acidosis, hyperosmolality, and insulin lack.
SAFETY RULE: Delay insulin if serum potassium is < 3.5 mmol/L <3.5\text{ mmol/L} < 3.5 mmol/L (2024 consensus; the 2009 guidance used 3.3), and replace potassium first.
Biological Danger: Insulin binds to cell surface receptors, stimulating N a + / K + Na^+/K^+ N a + / K + ATPase pumps that drive potassium rapidly from the extracellular fluid into the intracellular space. Rehydration and correction of acidosis also push potassium intracellularly. Administering insulin to a client with pre-existing hypokalemia causes serum potassium to collapse, triggering lethal ventricular dysrhythmias (ventricular fibrillation, torsades de pointes, asystole) and diaphragmatic respiratory arrest.
Potassium Management Algorithm:
If Serum K + < 3.5 mmol/L K^+ < 3.5\text{ mmol/L} K + < 3.5 mmol/L : Hold insulin. Give IV potassium chloride at about 10–20 mmol/h until potassium is above 3.5 mmol/L, then start insulin. Faster replacement needs central access and cardiac monitoring.
If Serum K + K^+ K + is 3.5 to 5.0 mmol/L 3.5\text{ to }5.0\text{ mmol/L} 3.5 to 5.0 mmol/L : Start insulin and add 10–20 mmol of KCl to each litre of IV fluid, keeping potassium between 4.0 and 5.0 mmol/L .
If Serum K + > 5.0 mmol/L K^+ > 5.0\text{ mmol/L} K + > 5.0 mmol/L : Give no potassium. Start insulin and fluids, and recheck potassium every 2 hours.
Pillar 3: Continuous Intravenous Regular Insulin Infusion
Insulin Formulation: Only Regular Insulin (short-acting) can be administered intravenously.
Infusion Dosing: Give a fixed-rate IV infusion of regular insulin at 0.1 units/kg/h in moderate or severe DKA. A 0.1 units/kg IV bolus may be given if setting up the infusion is delayed. Use 0.05 units/kg/h in HHS without significant ketosis.
Target Glycemic Rate of Decline: Adjust the insulin infusion to achieve a safe, steady decline in blood glucose of 50 to 75 mg/dL per hour (2.8 to 4.2 mmol/L/hr).
If glucose drops faster than 75 to 100 mg/dL/hr, reduce insulin rate or increase dextrose concentration to avert cerebral edema.
If glucose fails to decline by at least 50 mg/dL in the first hour, verify IV patency and fluid hydration; if hydration is adequate, double the insulin infusion rate.
Resolution Criteria (2024 consensus):
DKA is resolved when plasma ketones (beta-hydroxybutyrate) are below 0.6 mmol/L and venous pH is 7.3 or more or bicarbonate is 18 mmol/L or more .
HHS is resolved when calculated osmolality is below 300 mOsm/kg, urine output exceeds 0.5 mL/kg/h, cognition has improved and glucose is below 250 mg/dL.
The Subcutaneous Transition Bridge: Do not discontinue the IV insulin infusion until the client is awake, alert, tolerating oral food, and a dose of subcutaneous basal insulin (e.g., glargine or detemir) has been administered 1 to 2 hours prior to stopping the IV infusion . Because IV regular insulin has an ultra-short half-life (approx. 5 to 9 minutes), discontinuing the drip without prior basal insulin coverage causes rapid rebound hyperglycemia and recurrence of ketoacidosis.
Pillar 4: Acid-Base & Bicarbonate Restrictions
Routine sodium bicarbonate administration is strictly avoided in DKA. Clinical trials confirm that bicarbonate therapy fails to improve morbidity or mortality and causes significant harm: paradoxical intracellular central nervous system acidosis (exogenous bicarbonate converts to C O 2 CO_2 C O 2 , which freely crosses the blood-brain barrier while bicarbonate cannot), acute hypocalcemia, severe hypokalemia, and delayed clearance of blood ketoacids.
Exception: The 2024 consensus says bicarbonate may be considered only if pH is below 7.0 . The dose is 100 mmol of 8.4% sodium bicarbonate in 400 mL sterile water, repeated every 2 hours until pH exceeds 7.0.
Severe Hypoglycemia: Emergency Recognition & Tiered Protocols
Hypoglycemia is defined as a blood glucose level < 70 mg/dL <70\text{ mg/dL} < 70 mg/dL (3.9 mmol/L) . Severe, clinically significant hypoglycemia is defined as < 54 mg/dL <54\text{ mg/dL} < 54 mg/dL (3.0 mmol/L) or any episode producing severe cognitive impairment, seizures, or coma requiring external intervention.
Symptom Spectrum: Neurogenic vs. Neuroglycopenic
Neurogenic (Autonomic Warning Signs): Triggered by sympathoadrenal activation releasing epinephrine and norepinephrine: diaphoresis, tremors, tachycardia, palpitations, pallor, anxiety, tingling, and hunger. Clinical Pearl: Clients on non-selective beta-blockers (e.g., propranolol) or with chronic diabetic autonomic neuropathy experience hypoglycemia unawareness ; beta-blockers mask adrenergic signs (tachycardia, palpitations, tremors), leaving diaphoresis as the primary observable clue.
Neuroglycopenic (Cerebral Glucose Starvation Signs): Triggered by inadequate neuronal glucose delivery: confusion, irrational behavior, irritability, slurred speech, ataxia, diplopia, drowsiness, focal neurological deficits (mimicking stroke), seizures, coma, and brain death.
- Tiered Emergency Management Protocols ACUTE HYPOGLYCEMIA (< 70 mg/dL or symptomatic)
- |
- +--------------------------------+--------------------------------+
- | |
- CONSCIOUS & ABLE TO SWALLOW UNCONSCIOUS, OBTUNDED, OR NPO
- | |
- RULE OF 15 ESTABLISH AIRWAY / LATERAL POSITION
- | |
- Administer 15-20 g Fast-Acting Simple Carbs +---------------------+---------------------+
- 4 oz (120 mL) Fruit Juice or Regular Soda | |
- 3-4 Glucose Tablets or 1 Tube Glucose Gel IV ACCESS PRESENT NO IV ACCESS
- (Avoid high-fat milk or chocolate) | |
- | Administer 25-50 mL of D50W Administer Glucagon 1 mg
- Wait 15 Minutes & Retest Glucose Slow IV Push over 2-3 min IM or SC Injection
- | (Confirm patent large-bore IV; (Turn client on side;
- +-------------+-------------+ extravasation vesicant risk) emesis upon waking)
- | | | |
- Glucose < 70 mg/dL Glucose >= 70 mg/dL +-------------------+-------------------+
- | | |
- Repeat 15 g Simple Provide Complex Carb + Protein Wait 15 Minutes & Retest Glucose
- Carbohydrate Bolus Snack (Crackers + Peanut Butter) |
- if next meal is > 1 hour away If Glucose < 70 mg/dL: Repeat Dose
Conscious Client (The Rule of 15):
Administer 15 to 20 grams of rapid-acting simple carbohydrate : 4 ounces (120 mL) of fruit juice or regular soda, 3 to 4 glucose tablets, or 1 tube of oral glucose gel.
Avoid complex carbohydrates or high-fat foods (e.g., chocolate bars, ice cream, whole milk); fat delays gastric emptying and slows intestinal glucose absorption.
Re-test capillary blood glucose in 15 minutes .
If blood glucose remains < 70 mg/dL <70\text{ mg/dL} < 70 mg/dL , repeat 15 grams of simple carbohydrates.
Once blood glucose normalizes ( ≥ 70 mg/dL \ge 70\text{ mg/dL} ≥ 70 mg/dL ), administer a snack containing complex carbohydrates and protein (e.g., peanut butter crackers, half a sandwich) if the next meal is > 1 hour >1\text{ hour} > 1 hour away.
Unconscious, Obtunded, or NPO Client:
Airway & Positioning: Maintain airway patency; place the client in the lateral recovery position to prevent aspiration.
IV Access Present: Administer 25 to 50 mL of 50% Dextrose in Water (D50W) slow IV push over 2 to 3 minutes.
Nursing Safety Warning: D50W is an extreme hypertonic vesicant ( ≈ 2 , 525 mOsm/L \approx 2,525\text{ mOsm/L} ≈ 2 , 525 mOsm/L ). Confirm blood return from a patent, large-bore IV prior to administration; extravasation causes chemical cellulitis, tissue necrosis, and skin ulceration.
No IV Access: Administer Glucagon 1 mg intramuscularly (IM) or subcutaneously (SC) (or 3 mg intranasal glucagon powder).
Clinical Caveat: Glucagon stimulates hepatic glycogenolysis; it is ineffective in clients with depleted hepatic glycogen reserves (e.g., severe malnutrition, chronic alcoholism, prolonged fasting). Position the client on their side, as glucagon commonly provokes nausea and vomiting upon awakening.